TALDO1 and Cirrhosis: As newly unveiled by this study, heterozygous TAL deficiency predisposes to APAP‐induced liver injury in human subjects similar to the mouse model.8 Importantly, NAC treatment prevents APAP‐induced liver injury as well as cirrhosis and HCC in TAL‐deficient mice.8 Based two promising cases of NAC efficacy in patients with TAL deficiency, genetic screening and early detection should be vigorously pursued to allow for such preventative intervention and to avert severe morbidities in human subjects.